Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2013

Accounting Policies [Abstract]

Schedule of Revenue by Major Customers

		Three Months Ended June 30,				Six Months Ended June 30,
Licensee	Product Name	2013		2012		2013		2012
Genentech	Avastin®	33	%	33	%	34	%	32	%
	Herceptin®	33	%	35	%	33	%	35	%
	Lucentis®	21	%	22	%	18	%	19	%
Biogen Idec1	Tysabri®	9	%	10	%	11	%	12	%